Towa Pharmaceutical Co., Ltd.

As of March 31, 2026, Towa Pharmaceutical Co., Ltd. carries a market capitalization of 1.04B, placing it among publicly traded companies globally. Its enterprise value stands at 2.03B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Towa Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 11, 2026.

As of March 31, 2026, Towa Pharmaceutical Co., Ltd. has 49.23M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Towa Pharmaceutical Co., Ltd. maintains a current ratio of 2.76, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026.

As of the close on October 22, 2026, Towa Pharmaceutical Co., Ltd.'s stock has gained approximately 25.95% over the past 52 weeks. The 50-day moving average sits at 19.82, while the 200-day moving average is 20.56.

As of March 31, 2026, Towa Pharmaceutical Co., Ltd. holds 247.00M in cash and equivalents against 1.24B in total debt, resulting in a net debt position of 909.90M. Total book value stands at 970.97M, with working capital of 929.39M providing operational flexibility.

Towa Pharmaceutical Co., Ltd.'s most recent stock split took place on March 27, 2019 with a 1:3 split ratio.